Clicky

Amplia Therapeutics Limited(ATX)

Description: Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3). FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).


Keywords: Medicine Pharmaceutical Cancer Disease Drugs Oncology Tumor Chemotherapy Ovarian Cancer Chronic Disease Fibrosis Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Cancer Research Ptk2 Chemotherapies Pancreatic And Ovarian Cancer

Home Page: www.ampliatx.com

ATX Technical Analysis

350 Queen Street
Melbourne, VIC 3000
Australia
Phone: 61 2 8003 3650


Officers

Name Title
Dr. Christopher J. Burns B.Sc., BSc(Hons), Ph.D. CEO, MD & Director
Mr. Hamish George Chief Financial Officer
Ms. Rhiannon Jones B.Sc., Ph.D. Chief Operating Officer
Ms. Terrie-Anne Cock Ph.D. Head of Translational Biology
Mr. Andrew John Cooke FAICS, FCIS, FGIA, L.L.B., LLB, MAICD Company Sec.
Dr. Frank Gelder Founding Scientist
Dr. James A. Taylor Ph.D. Trials Consultant
Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR Trials Consultant
Dr. Benjamin M. Segal Clinical Consultant
Dr. Frederick E. Reno Ph.D. Toxicology Consultant

Exchange: AU

Country: AU

Currency: Australian Dollar (A$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9171
Price-to-Sales TTM: 5.1905
IPO Date:
Fiscal Year End: March
Full Time Employees: 0
Back to stocks